Bone Biologics (BBLG) Short Interest Ratio & Short Volume

Short interest is the volume of Bone Biologics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 19,700 shares of BBLG short. 3.87% of Bone Biologics' shares are currently sold short. Learn More on Bone Biologics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.87% of Bone Biologics' floating shares are currently sold short.

Bone Biologics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 19,700 shares, an increase of 51.5% from the previous total of 13,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Bone Biologics currently has issued a total of 530,000 shares. Some of Bone Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Bone Biologics currently has a public float of 508,800 shares.

3.87% of Bone Biologics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Bone Biologics: NanoVibronix, Inc. (0.10%), Acutus Medical, Inc. (1.44%), Virax Biolabs Group Limited (0.04%), Nemaura Medical Inc. (0.34%), Aethlon Medical, Inc. (3.04%), Panbela Therapeutics, Inc. (2.36%), Helius Medical Technologies, Inc. (7.57%), Bluejay Diagnostics, Inc. (3.91%), NeuBase Therapeutics, Inc. (0.51%), Biodexa Pharmaceuticals Plc (160.06%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling BBLG is an investing strategy that aims to generate trading profit from Bone Biologics as its price is falling. BBLG shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Bone Biologics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BBLG, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BBLG, twice per month. The most recent reporting period available is April, 30 2024.